Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
D'autres épisodes de "Kidney360"



Ne ratez aucun épisode de “Kidney360” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.








